The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The relationship between age and survival outcomes for eribulin in metastatic breast cancer.
C. Twelves
Consultant or Advisory Role - Eisai
Honoraria - Eisai
Research Funding - Eisai
L. T. Vahdat
Consultant or Advisory Role - Bristol-Myers Squibb; Eisai
Honoraria - Bristol-Myers Squibb; Eisai
Research Funding - Bristol-Myers Squibb; Celldex; Eisai; ImClone Systems; Novartis
J. Cortes
Consultant or Advisory Role - Eisai; Roche
Honoraria - Roche
J. Wanders
Employment or Leadership Position - Eisai
C. E. Dutcus
Employment or Leadership Position - Eisai
S. Seegobin
Employment or Leadership Position - Eisai
H. B. Muss
Consultant or Advisory Role - Eisai